Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10,678.00
Bid: 10,688.00
Ask: 10,690.00
Change: -64.00 (-0.60%)
Spread: 2.00 (0.019%)
Open: 10,756.00
High: 10,780.00
Low: 10,674.00
Prev. Close: 10,742.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EU snubs extra 300 mln J&J, Astra shots in bet on Pfizer-source

Wed, 21st Apr 2021 14:30

* EU is not taking extra doses under existing contracts

* No decision on whether EU may seek new AZ, J&J contracts

* EU betting on mRNA vaccines, in talks for Pfizer mega-deal

By Francesco Guarascio

BRUSSELS, April 21 (Reuters) - The European Union won't take
up an extra 300 million doses of AstraZeneca and Johnson
& Johnson COVID-19 vaccines that it has secured as
options under existing contracts, a senior EU official told
Reuters.

The decision is the latest sign Brussels is looking to
distance itself from AstraZeneca amid simmering tensions after
the drugmaker slashed its delivery targets due to production
problems.

It is also further evidence the bloc is sidelining vaccines
that have been linked with a very rare, but potentially fatal
side effect, and is confident current suppliers - led by
Pfizer/BioNTech - will deliver enough doses to
inoculate at least 70% of EU adults by the end of the summer.

Recently, the EU has sought to buy more shots from Pfizer
and its partner BioNTech, stepping up its bets on the messenger
RNA (mRNA) technology they use, as opposed to the viral vector
technology used by AstraZeneca and J&J.

The 27-nation bloc has a contract for a total of 400 million
doses with J&J, of which only 200 million have already been
ordered, and a separate contract with AstraZeneca for 400
million shots, of which only 300 million have been bought.

"There is no need to exercise the options" for the extra
doses, the official who is directly involved in talks with
vaccine makers said.

EU governments are under pressure to accelerate vaccination
programmes, which have lagged those in Britain and the United
States due to supply delays and safety concerns, to help tame a
third wave of infections.

A spokesman for the European Commission, which coordinates
talks with vaccine makers, said options can be exercised at any
time, but declined further comment.

The official, who asked not to be named because the matter
is confidential, said discussions were ongoing about further
supplies for booster shots and coronavirus variants, and it was
premature to rule AstraZeneca and J&J out of future contracts.

But the technology on which their shots are based is less
appealing than other vaccine platforms, the official said. Last
week, Italian newspaper La Stampa said the EU would not renew
contracts with the companies when they expire.

Both vaccines have been linked to very rare cases of blood
clots, which have led to temporary suspensions of their rollout
in Europe, although the EU drugs regulator has concluded the
benefits of both vaccines outweigh the risks.

Both companies have also had production problems, with
AstraZeneca in particular slashing its EU supply targets by two
thirds to 100 million doses by the end of June, sparking fury in
Brussels.

The EU official said AstraZeneca's supply problems had
convinced EU negotiators not to seek the optional doses from the
company. Under the contract, that option should have been
exercised by early March, although the EU could have still tried
to order more doses after then.

A spokesman for AstraZeneca declined to comment.

The EU official added that, in the case of J&J, initial
safety concerns about viral vector technology had pushed
negotiators not to seek optional doses and might also prevent
talks for a new contract.

A spokeswoman for J&J declined to comment.

The EU's existing COVID-19 vaccine contracts have been
widely criticised for being too lenient with companies because
they set quarterly rather than monthly delivery targets,
although other countries have done the same.

Last week, the Commission said it was starting talks with
Pfizer and BioNTech to buy up to 1.8 billion vaccine doses for
the coming years under a new contract with monthly targets, as
it prepares for the possible spread of new virus variants and
potential waning protection from initial shots.

The EU source said the new contract with Pfizer and BioNTech
was expected to meet a large share of the EU's demand in 2022
and 2023.

The bloc, with a population of nearly 450 million, has
already ordered 600 million Pfizer/BioNTech vaccines for this
year. It has also bought 310 million doses from Moderna
to be delivered this year, and has an option to buy another 150
million doses next year. Moderna also uses mRNA technology.

The EU also has contracts with CureVac and Sanofi, but
neither of them has completed clinical trials.
(Reporting by Francesco Guarascio @fraguarascio;
Editing by Josephine Mason and Mark Potter)

More News
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.